期刊文献+

功能性腹胀发病机制的研究 被引量:26

The pathogenesis of functional abdominal bloating
下载PDF
导出
摘要 目的探讨功能性腹胀的发病机制。方法对符合罗马Ⅲ标准的64例功能性腹胀患者、33例便秘型肠易激综合征(IBS)伴中重度腹胀患者、33例功能性便秘伴中重度腹胀患者及20例正常对照者进行研究。应用X线腹部立位平片对肠道气体量进行评估;采用乳果糖呼氢的方法对肠道菌群改变进行评估;采用不透X线的标志物测定4h胃及48h结肠排空率;采用ELISA法测定空腹血清降钙素基因相关肽(CGRP)及P物质的水平对患者内脏敏感性状况进行评估;采用SAS及SDS量表对心理因素进行评分。结果①乳果糖呼氢阳性率、胃肠排空率、血清CGRP、血清P物质含量及SDS、SAS评分各组间比较差异均有统计学意义(P均<0.05),而肠道气体量各组间比较无统计学差异(P>0.05)。②功能性腹胀组与正常对照组比较,乳果糖呼氢阳性率、胃肠排空率、血清P物质含量及SDS和SAS评分差异有统计学意义(P均<0.05),而肠道气体量与血清CGRP含量相比较则无统计学差异(P均>0.05)。结论功能性腹胀的发病可能与患者肠道菌群异常、胃肠运动功能障碍、精神心理异常、内脏高敏感性有关,而与肠道气体产生量无关。 Objective To investigate the pathogenesis of functional abdominal bloating (FAB). Methods All of the subjects recruited met the Rome m Diagnostic Criteria: 64 patients with functional abdominal distension, 33 patients with constipation-predominant irritable bowel syndrome (IBS) with moderate to severe abdominal bloating, 33 patients with functional constipation (FC) with moderate to severe abdominal bloating, and 20 healthy volunteers. Abdominal plain films were used to assess the intestinal gas volume increase. Lactulose hydrogen breath test (LHBT) was used to analyze whether the alteration of intestinal flora was present. Gastric and gut emptying rates were evaluated by non-radio-paque marks at 4 h and 48 h. The concentrations of fasting serum substance P (SP) and calcitonin gene related peptide (CGRP) were measured by ELISA method. Psychosocial risk factors were assessed with self-rating depression scale (SDS) and self-rating anxiety scale (SAS). Results The positive rate of LHBT, gastric and gut emptying, serum CGRP and SP concentrations, and SAS and SDS scores differed significantly among the 4 groups (all P^0.05), but intestinal gas volumes had no difference (P~〉0.05). FAB and control groups differed obviously in the positive rate of LHBT, gastrointestinal emptying rate, serum SP concentration, and SAS and SDS scores (all P 〈 0. 05), but not in intestinal gas volumes or serum CGRP concentration (both P〉0.05). Conclusion Alteration of intestinal flora, gastrointestinal dysfunction, visceral hypersensitivity and abnormal psychological factors may play more prominent roles in the pathogenesis of FAB than the increase of intestinal gas contents.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2013年第6期789-792,802,共5页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 功能性腹胀 乳果糖呼氢试验 肠易激综合征 功能性便秘 肠道菌群 肠道气体 functional abdominal bloating (FAB) lactulose hydrogen breath test irritable bowel syndrome functional constipation~ intestinal bacterial intestinal gas
  • 相关文献

参考文献24

  • 1MARATKA Z. Abdominal bloating and distension in functionalgastrointestinal disorders- epidemiology and possible mecha-nisms [J]. Aliment Pharmacol Ther,2008,27 (8) : 713-4; au-thor reply 714.
  • 2AGRAWAL A, WHORWELL PJ. Abdominal bloating and dis-tension in functional gastrointestinal disorders epidemiology andexploration of possible mechanisms [J]. Aliment PharmacolTher, 2008, 27(1):2-10.
  • 3罗金燕.功能性肠病与罗马Ⅲ[J].胃肠病学,2006,11(12):739-740. 被引量:23
  • 4DROSSMAN DA. The functional gastrointestinal disorders andthe Rome M process [J]. Gastroenterology, 2006,130(5):1377-1390.
  • 5NOBAEK S, JOHANSSON ML,MOLIN G,et al. Alterationof intestinal microflora is associated with reduction in abdomi-nal bloating and pain in patients with irritable bowel syndrome[J]. A J Gastroenterol, 2000,95: 1231-1238.
  • 6MCMANIS PG, NEWALL D,TALLEY NJ. Abdominal wall mus-cle activity in irritable bowel syndrome with bloating [J]. Am JGastroenterol? 2001, 96(4) :1139-1142.
  • 7VILLORIA A,AZPIROZ F, SOLDEVILLA A, et al. Ab-dominal accommodation : a coordinated adaptation of the ab-dominal wall to its content [J]. Am J Gastroenterol,2008,103(11):2807-2815.
  • 8BORTOLOTTI M, LUGLI A. What is the origin of postpran-dial abdominal distension in patients with functional bloatingand irritable bowel syndrome[J]? Scand J Gastroenterol, 2009,44(3):383-384.
  • 9PARAMO HERNANDEZ DB. Bloating and abdominal disten-tion: Just gas? A look in the direction of physiology [J]. RevCol Gastroenterol, 2011,26(4):266-272.
  • 10LEVITT MD, FURNE J, AEOLUS MR, et al. Evaluation ofan extremely flatulent patient: case report and proposed diag-nostic and therapeutic approach [J]. Am J Gastroenterol,1998, 93(11):2276-2281.

二级参考文献13

  • 1Wald A,Hinds JP,Caruana BJ.Psychological and physiological characteristics of patients with severe idiopathic constipation.Gastroenterology,1989,97:932~937.
  • 2Jones MP,Talley NJ,Nuyts G,Dubois D.Lack of objective evidence of efficacy of laxatives in chronic constipation.Dig Dis Sci,2002,47:2222~2230.
  • 3Lederle FA,Busch DL,Mattox KM,West MJ,Aske DM.Cost-effective treatment of constipation in the elderly:a randomized double-blind comparison of sorbitol and lactulose.Am J Med,1990,89:597~601.
  • 4Johanson JF,Wald A,Tougas G,Chey WD,Novick JS,Lembo AJ,Fordham F,Guella M,Nault B.Effect of tegaserod in chronic constipation:a randomized,doubleblind,controlled trial.Clin Gastroenterol Hepatol,2004,2:796~805.
  • 5Kamm MA,Muller-Lissner S,Talley NJ,Tack J,Boeckxstaens G,Minushkin ON,Kalinin A,Dzieniszewski J,Haeck P,Fordham F,Hugot-Cournez S,Nault B.Tegaserod for the treatment of chronic constipation:a randomized,double-blind,placebo-controlled multinational study.Am J Gastroenterol,2005,100:362~372.
  • 6Afzalpurkar RG,Schiller LR,Little KH,Santangelo WC,Fordtran JS.The self-limited nature of chronic idiopathic diarrhea.N Engl J Med,1992,327:1849~1852.
  • 7Longstreth GF,Thompson WG,Chey WD,Houghton LA,Mearin F,Spiller RC.Functional bowel disorders.Gastroenterology,2006,130:1480~1491.
  • 8Kim H J,Camilleri M,McKinzie S,Lempke MB,Burton DD,Thomforde GM,Zinsmeister AR.A randomized controlled trial of a probiotic,VSL#3,on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther,2003,17:895~904.
  • 9Suarez F,Levitt MD,Adshead J,Barkin JS.Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal.Dig Dis Sci,1999,44:1317~1321.
  • 10Kellow J,Lee OY,Chang FY,Thongsawat S,Mazlam MZ,Yuen H,Gwee KA,Bak YT,Jones J,Wagner A.An Asia-Pacific,double blind,placebo controlled,randomised study to evaluate the efficacy,safety,and tolerability of tegaserod in patients with irritable bowel syndrome.Gut,2003,52:671~676.

共引文献22

同被引文献263

引证文献26

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部